Reaction

Pulmonary Tuberculosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,210 reports · 118 co-occurring drugs

As of the last recalculation, Pulmonary Tuberculosis appears in 4,210 FAERS reports alongside 118 co-occurring drug terms. The strongest observed disproportionality signal is PYRAZINAMIDE (PRR 132.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pyrazinamide	238	132.7	136.2
Isoniazid	282	92.2	93.8
Rifampicin	142	71.8	72.8
Efavirenz	102	46.3	46.8
Rifampin	104	36.1	36.3
Lamivudine Oral	126	25.4	25.5
Nevirapine	42	23.2	23.3
Infliximab	816	22.7	22.8
Lamivudine	134	22.1	22.2
Tenofovir Disoproxil Fumarate Tablets	38	21.9	22.0
Adalimumab-Fkjp	155	17.1	17.2
Adalimumab-Aaty	155	16.8	16.8
Moxifloxacin	47	16.7	16.7
Zidovudine	43	16.1	16.1
Adalimumab-Adaz	158	15.3	15.4
Lopinavir And Ritonavir	41	15.1	15.1
Moxifloxacin Hydrochloride	52	12.8	12.9
Abacavir Sulfate	24	12.2	12.3
Linezolid	72	12.1	12.2
Prednisolone	392	11.7	11.8
Prednisolone Oral	392	11.7	11.8
Prednisolone Oral Solution	392	11.7	11.8
Azathioprine	197	11.5	11.6
Raltegravir	37	11.2	11.2
Ganciclovir Sodium	20	9.4	9.4
Basiliximab	22	9.3	9.3
Ganciclovir	19	9.2	9.2
Valganciclovir Hydrochloride Powder,	21	8.5	8.6
Golimumab	141	8.4	8.4
Methotrexate	599	8.0	8.0
Amikacin	27	7.9	7.9
Ritonavir 100 Mg	23	7.6	7.7
Methotrexate Sodium	632	7.4	7.4
Mycophenolate Mofetil	184	7.0	7.0
Mycophenolate Mofetil Hydrochloride	184	6.9	7.0
Valganciclovir	24	6.3	6.3
Valganciclovir Hydrochloride	24	6.3	6.3
Tacrolimus Ointment 0.1%	154	6.3	6.3
Tacrolimus Extended-Release Capsules	154	6.3	6.3
Tenofovir Disoproxil Fumarate	41	6.2	6.2
Anti-Thymocyte Globulin (Rabbit)	10	6.1	6.1
Durvalumab	25	6.1	6.1
Tacrolimus	183	6.0	6.0
Darunavir	18	5.9	5.9
Methylprednisolone	159	5.9	5.9
Everolimus Tablets	19	5.6	5.6
Ritonavir	33	5.6	5.6
Sulfasalazine	85	5.5	5.5
Mesalamine	61	5.4	5.4
Emtricitabine And Tenofovir Disoproxil Fumarate	49	5.4	5.4
Cimetidine	10	5.1	5.1
Tretinoin	8	4.9	4.9
Remdesivir	13	4.8	4.8
Baricitinib	9	4.6	4.6
Misoprostol	9	4.6	4.6
Levofloxacin	55	4.6	4.6
Levofloxacin In 5% Dextrose	55	4.6	4.6
Ceftriaxone Sodium	35	4.5	4.5
Imatinib	16	4.5	4.5
Atazanavir	13	4.5	4.5
Cyclosporine	99	4.5	4.5
Ceftriaxone	29	4.4	4.4
Amphotericin B	11	4.3	4.4
Fludarabine Phosphate	34	4.3	4.3
Hydroxychloroquine	63	4.2	4.2
Busulfan	13	4.1	4.1
Voriconazole Injection	17	3.9	3.9
Dolutegravir Sodium	7	3.8	3.8
Entecavir	9	3.8	3.8
Certolizumab Pegol	89	3.8	3.8
Leflunomide	79	3.8	3.8
Bendamustine Hydrochloride	9	3.7	3.7
Ixazomib	21	3.6	3.6
Cyclophosphamide Injection, Solution	126	3.6	3.6
Cyclophosphamide	126	3.6	3.6
Cyclophosphamide For Injection	126	3.6	3.6
Voriconazole	21	3.4	3.4
Ribavirin	44	3.4	3.4
Febuxostat Tablets 40 Mg	7	3.4	3.4
Febuxostat Tablets 80 Mg	7	3.4	3.4
Mycophenilic Acid	14	3.3	3.3
Anakinra	11	3.3	3.3
Adalimumab	427	3.2	3.2
Nivolumab	61	3.2	3.2
Tofacitinib Citrate	8	3.0	3.0
Obinutuzumab	10	3.0	3.0
Meropenem	19	2.9	2.9
Sorafenib	12	2.9	2.9
Gefitinib	5	2.7	2.7
Gemcitabine	20	2.5	2.5
Imatinib Mesylate	14	2.5	2.5
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	9	2.5	2.5
Doxorubicin	44	2.5	2.5
Irinotecan Hydrochloride	6	2.3	2.3
Peginterferon Alfa-2A	25	2.3	2.3
Ruxolitinib	33	2.3	2.3
Gemcitabine Hydrochloride	24	2.2	2.2
Bendamustine Hcl	7	2.2	2.2
Cisplatin	35	2.2	2.2
Pembrolizumab	46	2.2	2.2
Docetaxel Anhydrous	28	2.1	2.1
Docetaxel	28	2.1	2.1
Azacitidine For	7	1.9	1.9
Etanercept	224	1.9	1.9
Panitumumab	6	1.9	1.9
Pemetrexed	8	1.8	1.8
Dasatinib	13	1.7	1.7
Belimumab	11	1.7	1.7
Azacitidine	10	1.7	1.7
Ustekinumab	34	1.6	1.6
Crizotinib	4	1.6	1.6
Sofosbuvir	6	1.5	1.5
Ipilimumab	13	1.5	1.5
Daratumumab	12	1.5	1.5
Guselkumab	9	1.2	1.2
Osimertinib	8	1.2	1.2
Velpatasvir And Sofosbuvir	3	1.2	1.2
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	5	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.